Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Gene therapy in Rare Diseases - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.
Gene therapy in Rare Diseases Pipeline Insight, 2024 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Gene therapy in Rare Diseases market.
A detailed picture of the Gene therapy in Rare Diseases pipeline landscape is provided, which includes the disease overview and Gene therapy in Rare Diseases treatment guidelines. The assessment part of the report embraces in-depth Gene therapy in Rare Diseases commercial assessment and clinical assessment of the Gene therapy in Rare Diseases pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gene therapy in Rare Diseases collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Gene therapy in Rare Diseases of Pipeline Development Activities
- All of the companies that are developing therapies for the treatment of Gene therapy in Rare Diseases with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Gene therapy in Rare Diseases treatment.
- Gene therapy in Rare Diseases key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Gene therapy in Rare Diseases market.
Scope of the Report
- The Gene therapy in Rare Diseases report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Gene therapy in Rare Diseases across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Gene therapy in Rare Diseases therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Gene therapy in Rare Diseases research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Gene therapy in Rare Diseases.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Gene therapy in Rare Diseases.
- In the coming years, the Gene therapy in Rare Diseases market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
Key Questions
- What are the current options for Gene therapy in Rare Diseases treatment?
- How many companies are developing therapies for the treatment of Gene therapy in Rare Diseases?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Gene therapy in Rare Diseases?
- How many Gene therapy in Rare Diseases emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Gene therapy in Rare Diseases?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Gene therapy in Rare Diseases market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Gene therapy in Rare Diseases?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Gene therapy in Rare Diseases therapies?
- What are the clinical studies going on for Gene therapy in Rare Diseases and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Gene therapy in Rare Diseases?
- How many patents are granted and pending for the emerging therapies for the treatment of Gene therapy in Rare Diseases?
Key Topics Covered:
1. Report Introduction
2. Gene therapy in Rare Diseases
2.1. Overview
2.2. History
2.3. Gene therapy in Rare Diseases Symptoms
2.4. Causes
2.5. Pathophysiology
2.6. Gene therapy in Rare Diseases Diagnosis
2.6.1. Diagnostic Guidelines
3. Gene therapy in Rare Diseases Current Treatment Patterns
3.1. Gene therapy in Rare Diseases Treatment Guidelines
4. Gene therapy in Rare Diseases - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Gene therapy in Rare Diseases companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Gene therapy in Rare Diseases Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Gene therapy in Rare Diseases Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Gene therapy in Rare Diseases Late Stage Products (Phase-III)
7. Gene therapy in Rare Diseases Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Gene therapy in Rare Diseases Discontinued Products
13. Gene therapy in Rare Diseases Product Profiles
13.1. Product Description
13.1.1. Product Overview
13.1.2. Mechanism of action
13.2. Research and Development
13.2.1. Clinical Studies
13.3. Product Development Activities
13.3.1. Collaboration
13.3.2. Agreements
13.3.3. Acquisition
13.3.4. Patent Detail
13.4. Tabulated Product Summary
13.4.1. General Description Table
Detailed information in the report
14. Gene therapy in Rare Diseases Key Companies
15. Gene therapy in Rare Diseases Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Gene therapy in Rare Diseases Unmet Needs
18. Gene therapy in Rare Diseases Future Perspectives
19. Gene therapy in Rare Diseases Analyst Review
20. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/wsgf2o
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
